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L-Carnitine plays an important role in lipid metabolism by facilitating the transport of long-chain fatty acids across the mitochondrial inner
membrane followed by fatty acid beta-oxidation. It is known that L-carnitine exists as a zwitterion and that member of the OCTN family play an
important role in its transport. The aims of this study were to characterize L-carnitine transport in the intestine by using Caco-2 cells and to
elucidate the effects of levofloxacin (LVFX) and grepafloxacin (GPFX), which are zwitterionic drugs, on L-carnitine uptake. Kinetic analysis
showed that the half-saturation Na+ concentration, Hill coefficient and Km value of L-carnitine uptake in Caco-2 cells were 10.3±4.5 mM, 1.09
and 8.0±1.0 μM, respectively, suggesting that OCTN2 mainly transports L-carnitine. LVFX and GPFX have two pKa values and the existence
ratio of their zwitterionic forms is higher under a neutral condition than under an acidic condition. Experiments on the inhibitory effect of LVFX
and GPFX on L-carnitine uptake showed that LVFX and GPFX inhibited L-carnitine uptake more strongly at pH 7.4 than at pH 5.5. It was
concluded that the zwitterionic form of drugs plays an important role in inhibition of OCTN2 function.
© 2006 Elsevier B.V. All rights reserved.Keywords: L-carnitine; Caco-2; Levofloxacin; Grepafloxacin; OCTN21. Introduction
L-Carnitine plays an important role in lipid metabolism by
facilitating the transport of long-chain fatty acids across the
mitochondrial inner membrane followed by fatty acid beta-
oxidation [1,2]. L-Carnitine homeostasis in humans is main-
tained by acquisition from dietary sources, a modest rate of
endogenous biosynthesis and efficient reabsorption [3]. It is
known that carnitine deficiency causes cardiomyopathy, muscle
weakness, hypoketoic hypoglycemia, Reye's syndrome and
sudden infant death [4–6].
Recently, a novel organic cation transporter (OCTN) family
has been described, and it has been shown that some OCTNs are
capable of transporting L-carnitine [7,8]. OCTN2, a member of
the OCTN transporter family, is the most important L-carnitine
transporter. It has been reported that OCTN2 transports carnitine⁎ Corresponding author. Tel./fax: +81 11 706 3770.
E-mail address: ken-i@pharm.hokudai.ac.jp (K. Iseki).
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doi:10.1016/j.bbamem.2006.07.002Na+-dependently and that it contributes to L-carnitine home-
ostasis by transporting L-carnitine in various tissues [7].
Moreover, Elimrani et al. have reported the expression and
localization of OCTN2 in Caco-2 cells [9]. It has been also
reported that L-carnitine is transported by ATB0,+, an amino acid
transporter, in a low affinity and high capacity manner [10].
L-Carnitine deficiency is caused by a decrease in carni-
tine transport. It is known that mutation of OCTN2 decreases
L-carnitine transport and that it is one of the causes of primary
carnitine deficiency [11–13]. On the other hand, there are
some reports of carnitine deficiency being induced by several
drugs (valproic acid, cephaloridine, emetine and pivalic acid)
[14–17].
L-Carnitine is a highly-hydrosoluble compound and exists in
vivo as a zwitterion which has a quaternary amine and
carboxylate (pKa 3.8) [18]. OCTN2 is an important transporter
for L-carnitine but also transport many cationic drugs, including
tetraethylammonium, pyrilamine and verapamil [19]. More-
over, cephaloridine, which is a zwitterion, inhibits transport and
Fig. 1. Expression of OCTN1 and OCTN2 mRNA in Caco-2 cells. The mRNA
expression was determined by RT-PCR. Data shown are typical results from
three independent experiments.
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compound with an ionic charge is involved in OCTN2 substrate
recognition.
Levofloxacin (LVFX) and grepafloxacin (GPFX), a new
quinolone antibiotic, are zwitterions that each have a carbox-
ylate and an amine. We previously reported that transport of
enoxacin, also a new quinolone antibiotic, is stimulated by
diffusion potential in rat BBMVs and that the inhibitory effect
of ciplofloxacin on enoxacin absorption differs depending on
pH conditions [20,21]. It has also been reported that uptake of
LVFX and GPFX in Caco-2 cells under an acidic condition was
less than that under a neutral condition [22]. Moreover,
quinolones are substrates for the ABC transporter super family
[23–25]. However, the transport systems of LVFX and GPFX
have not been revealed clearly, and inhibitory effects on
transporters in the intestine have not been investigated in detail.
In this study, we investigated L-carnitine transport in the
intestine by using Caco-2 cells and elucidated the effects of LVFX
and GPFX representative zwitterionic drugs on L-carnitine
uptake. We also investigated whether the effect of quinolones
on L-carnitine uptake is changed by variation of the ionic charge of
quinolones.
2. Materials and methods
2.1. Chemicals
L-[3H]-carnitine (80.0 Ci/mmol) was purchased fromAmershamBiosciences
Corp. Levofloxacin was kindly donated by Daiichi Pharmaceutical Co., Ltd.
(Tokyo, Japan). Grepafloxacin was kindly supplied by Otsuka Pharmaceutical
Co., Ltd. (Tokyo, Japan). All other reagents were of the highest grade available
and used without further purification.Fig. 2. Immunohistochemistry of OCTN2 in Caco-2 cells. The nucleus was stained by
OCTN2 (green, b). Fluorescence was visualized by using a confocal microscope at2.2. Animals
Male Wistar rats, aged 6 to 7 weeks (300–350 g in weight), were obtained
from NRC Haruna (Gunma, Japan). The experimental protocols were reviewed
and approved by the Hokkaido University Animal Care Committee in
accordance with the “Guide for the Care and Use of Laboratory Animals”.
2.3. Cell Culture
Caco-2 cells obtained from American Type Culture Collection (Rockville,
MD) were maintained in plastic culture flasks (Falcon, Becton Dickinson and
Co., Lincoln Park, NJ) as described previously [26]. Themedium used for growth
of Caco-2 cells was Dulbecco's modified Eagle's medium (Gibco Life
Technologies, Inc., Grand Island, NY) with 10% fetal bovine serum (ICN
Biomedicals, Inc., Aurora, OH), 1% nonessential amino acids (Gibco), 4 mM
glutamine (Gibco), and 100 IU/mL penicillin–100 μg/mL streptomycin.
Monolayer cultures were grown in an atmosphere of 5% CO2–95% air at
37 °C. Cells reached confluency after 4–6 days in culture. The cells were
harvested with 0.25 mM trypsin and 0.2% EDTA (5 min at 37 °C), resuspended,
and seeded into a new flask. Cells between the 48th and 56th passages were used
in this study. For the uptake study, Caco-2 cells were seeded at a density of 2×105
cells/cm2 on 24-well plastic plates (Corning Coster Corp., Cambridge, MA). The
cell monolayers were fed a fresh growthmedium every 2 days andwere then used
at 4–6 days for the uptake experiments.
2.4. RT-PCR analysis
Total RNAwas prepared from Caco-2 cells using an Isogen (Nippon Gene,
Tokyo). Single-strand cDNA was made from 2 μg total RNA by reverse
transcription (RT) using an Omniscript RT Kit (QIAGEN). PCR was performed
using Hot Star Taq PCR (QIAGEN) with OCTN1-, OCTN2- and GAPDH-
specific primers through 35 cycles of 94 °C for 30 s, 50 °C for 1 min and 72 °C for
1 min. The primers specific to OCTN1, OCTN2 and GAPDH were designed on
the basis of sequence data in the GenBankTM database (accession no.:
NM_003059, NM_003060 andNM_002046, respectively). The sequences of the
specific primers were as follows: 5′-TGG AAT CTG GTG TGT GAG GA-3′
(sense) and 5′-CCT GAA CAG GTC CAG AAT GA-3′ (antisense) for OCTN1
(609 bp), 5′-CTG TTG GGC TCC TTC ATT TC-3′ (sense) and 5′-TGT TGT
GGG ACT GTT GCT TC-3′ (antisense) for OCTN2 (539 bp), 5′-TGG AAA
TCCCATCACCATCT-3′ (sense) and 5′-TTCTAGACGGCAGGTCAGGT-
3′ (antisense) for GAPDH (540 bp). A cDNA sample obtained from BeWo cells
was used for positive control experiment of the OCTN1 primer. The PCR
products were subjected to electrophoresis on a 1% agarose gel and then
visualized by ethidium bromide staining.
2.5. Immunocytochemistry
Caco-2 cells were fixed in 10% formaldehyde and permeabilized in 0.1%
Triton X-100 for 15 min. The cells were first incubated in a blocking buffer
(10% FBS in PBS) for 60 min. Then the cells were incubated overnight at 4 °C
with an anti-OCTN2 antibody (dilution of 1:20) (Santa Cruz Biotechnology,DAPI (blue, a). Expression of OCTN2 was determined using an antibody against
a magnification of ×40.
Fig. 3. Effect of replacement of Na+ with other cations on L-carnitine uptake.
L-[3H]-carnitine (5 nM) uptake was measured for 30 min. Na+ or Cl− in the
buffer was replaced with other cations or anions. Each point represents the mean
with S.D. of three determinations. **Significantly different from NaCl at p<0.01.
Fig. 5. Concentration dependence of L-carnitine uptake by Caco-2 cells. L-[3H]-
carnitine uptake by Caco-2 cells at various concentrations of L-[3H]-carnitine
from 5 nM to 25 μMwas measured for 30 min. The L-[3H]-carnitine uptake was
measured in a buffer containing Na+ (●) or NMDG+ (○). The dashed line shows
the Na+-dependent component of L-[3H]-carnitine uptake, determined by
subtracting NMDG+ from Na+ at each concentration of L-[3H]-carnitine uptake.
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temperature with an FITC-conjugated donkey anti-goat secondary antibody
(Santa Cruz Biotechnology) at a dilution of 1:200. Nuclei were stained with
DAPI and the cells were mounted in VECTASHIELD Mounting Medium
(Vector Laboratories, Burlingame, CA). The OCTN2 protein was visualized by
using a confocal microscope (Zeiss LSM-510; Carl Zeiss Inc., Thornwood, NY).
2.6. Uptake experiment
Uptake experiments using Caco-2 cells were carried out as described
previously [26]. The L-carnitine uptake was linear for 60 min. Therefore, the L-
carnitine uptake was determined at uptake time for 30 min in all uptake
experiments. The cells were washed two times with Hanks' balanced salt
solution (HBSS) containing 137 mM NaCl, 5.4 mM KCl, 1.3 mM CaCl2,
0.8 mM MgSO4, 0.3 mM KH2PO4, 0.4 mM NaH2PO4, 4.2 mM NaHCO3,
25 mM D-glucose, and 10 mM HEPES and then equilibrated in HBSS at 37 °C
for approximately 10 min. L-[3H]-Carnitine (0.25 μCi/mL) premixed with or
without inhibitors in warm HBSS was added to the cells in a shaking hot box
(37 °C). When required, Na+ was isosmotically substituted by N-methyl-D(−)-
glucamine (NMDG+) or other ions. The dosing solutionswere then aspirated, and
the cells were washed with ice-cold HBSS two times followed by addition of
0.5 mL of lysing solution (1% SDS in 0.2 N NaOH), and shaking of the plate in
the hot box was continued. Samples of the lysate were then collected for
scintillation spectrometry (1600 TR, Packard Instruments, Meriden, CT) and
protein assay by Lowry's method with bovine serum albumin as the standard.Fig. 4. Na+-dependent L-carnitine uptake (a) and Hill plot analysis (b). L-[3H]-carnitine
(a). L-[3H]-carnitine uptake is shown by a Hill plot (b). Na+ was replaced with NMD2.7. Oral administration experiment
Wistar rats were fasted overnight (16 h) prior to oral administration
experiment using L-[3H]-carnitine with a dose of 204 ng/kg (81 μCi/kg) in saline
solution. Blood samples (0.1mL)were collected into tubes from a cervical vein at
15, 30, 45, 60 and 90 min after administration of L-[3H]-carnitine. Following
centrifugation (3,000 rpm, 10 min), 20 μL of serum was used for scintillation
spectrometry (1600TR, Packard). In the case of inhibitory experiments, LVFX
was dissolved in L-[3H]-carnitine solution to a final concentration of 62.5 mM.
2.8. Analytical procedures
Student's t-test was used to determine the significance of differences
between two group means. For kinetic studies, the Michaelis–Menten constant
and the stoichiometry between L-carnitine and Na+ were fitted to the following
equations by a nonlinear least-squares regression analysis using Origin®
(version 6.1J):
v ¼ VmaxS=ðKm þ SÞ þ Kd S; ð1Þ
log½v=ðVmax  vÞ ¼ n log½Naþ  logKNa; ð2Þ
where v and S are the uptake rate and concentration of the substrate,
respectively, and Km, Vmax, KNa and n are the half-saturation concentration(5 nM) uptake was measured at Na+ concentrations from 0 to 140mM for 30 min
G+ to maintain osmolarity.
Fig. 6. Inhibitory effect of structure homologue on L-carnitine uptake. L-[3H]-carnitine (5 nM) uptake was measured for 30 min in the presence of 5 mM of each
structure homologue of L-carnitine except for unlabeled L-carnitine (0.5 mM). *Significantly different from no addition at p<0.05, **p<0.01.
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Na+ and Hill coefficient, respectively.
3. Results
3.1. Expression of OCTN family members in Caco-2 cells
In the first part of this study, we investigated the mRNA
expression levels of OCTN familymembers by RT-PCR analysis
using totalRNAisolated fromCaco-2cells andspecificprimersof
OCTN1andOCTN2.OCTN2andGAPDHmRNAweredetected
onsize for540bpclearly,but therewasnobandofOCTN1mRNAFig. 7. Theoretical ratio of zwitterionic forms of LVFX and GPFX under various pH
by using the Henderson–Hasselbalch equation.(Fig. 1). Furthermore, we performed immunocytochemistry to
investigate the expression of OCTN2 protein in Caco-2 cells. A
green signal (FITC, OCTN2) was observed around a blue signal
(DAPI, nucleus), suggesting that OCTN2 is expressed at the
plasma membrane (Fig. 2).
3.2. L-Carnitine uptake into Caco-2 cells
To study the effects of various cations on specificity of L-
carnitine uptake in Caco-2 cells, Na+ in the transport medium
was replaced with various cations. Fig. 3 shows that the level of
L-carnitine uptake was highest in the presence of Na+ andconditions. The ratios of zwitterionic forms of LVFX and GPFX were calculated
Fig. 8. Inhibitory effects of LVFX (a) and GPFX (b) on L-carnitine uptake at pH 5.5 and pH 7.4. L-[3H]-carnitine (5 nM) uptake at pH 5.5 or 7.4 was measured for
30 min in the presence of 5 mM of LVFX or 2 mM of GPFX. *Significantly different from no addition at p<0.05, **p<0.01.
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Furthermore, replacement of Cl− with other anions had no
effect on L-carnitine uptake.
Since L-carnitine transport by OCTN2 has been shown to be
Na+-dependent [27], we examined Na+-dependent uptake of L-
carnitine in Caco-2 cells (Fig. 4). It was found that L-carnitine
uptake is saturable, and nonlinear least-squares analysis showed
a half- saturation Na+ concentration of 10.3±4.5 mM (Fig. 4a).
Moreover, Hill plot analysis showed that the stoichiometry of
transport of L-carnitine and Na+ was 1.09, suggesting that one
Na+ molecule is associated with the transport of one molecule of
L-carnitine in Caco-2 cells (Fig. 4b).
To clarify L-carnitine uptake into Caco-2 cells in detail, the
concentration dependence of L-carnitine was studied. We
analyzed Na+-dependent L-carnitine uptake by subtracting the
Na+-independent component from total L-carnitine uptake
(Fig. 5). The Na+-dependent component of L-carnitine was
saturable. Nonlinear least-squares analysis showed a Km value
of 8.0±1.0 μM.Fig. 9. Inhibitory effects of various concentrations of LVFX (a) and GPFX (b) on L-ca
30 min in the presence of LVFX at concentrations of 0.1–50 mM (a) or in the presenc
7.4 at p<0.05, **p<0.01.3.3. Effects of structural homologues and quinolones on
L-carnitine uptake
The effects of structural homologues on L-carnitine uptake
were studied. As shown in Fig. 6, betaine and choline
significantly inhibited L-carnitine uptake. On the other hand,
glycine and L-lysine had no effect on L-carnitine uptake.
However, a significant inhibitory effect on L-carnitine uptake
was observed in a presence of trimethyl-L-lysine.
Since both LVFX and GPFX have a carboxylate and an
amine, they have two pKa values: 5.7 and 7.9 for LVFX and 7.1
and 8.8 for GPFX, respectively. We calculated the ratio of
zwitterions of these two quinolones under each pH buffer
condition. According to theoretical calculations, about 75% of
the total amount of LVFX and 64% of GPFX exist as
zwitterionic form under a pH 7.4 buffer condition. In contrast,
only 2% of the total amount of GPFX exists as a zwitterionic
form under a pH 5.5 buffer condition, while about 39% of LVFX
exists as a zwitterionic form under the same condition (Fig. 7).rnitine uptake. L-[3H]-carnitine (5 nM) uptake at pH 5.5 or 7.4 was measured for
e of GPFX at concentrations of 0.01–2 mM (b). *Significantly different from pH
Table 1
Ratio of zwitterionic form and IC50 value of quinolones on L-carnitine uptake
under each pH condition
Ratio of zwitterionic form (%) IC50
LVFX pH 5.5 39 36.1 mM
pH 7.4 75 6.8 mM
GPFX pH 5.5 2 –
pH 7.4 64 1.0 mM
Fig. 11. Inhibitory effect of LVFX on L-carnitine absorption from the rat
intestine. Serum concentration of L-carnitine was determined after a single p.o.
administration (204 ng/kg) in the absence (○) or presence (●) of LVFX at
62.5 mM. *Significantly different from control at p<0.05.
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under pH 5.5 and pH 7.4 buffer conditions were studied.
L-Carnitine uptake in the presence of 5 mM LVFX was
decreased to 60–80% of the control level under both buffer
conditions. On the other hand, while 2 mM GPFX inhibited
L-carnitine uptake significantly under a pH 7.4 buffer condition,
it had no effect on L-carnitine uptake under a pH 5.5 buffer
condition (Fig. 8).
To elucidate the effect of pH buffer condition on the
inhibitory mechanism of quinolones, we examined the inhib-
itory effects of various concentrations of LVFX and GPFX on
L-carnitine uptake under both pH 5.5 and 7.4 buffer conditions.
LVFX inhibited L-carnitine uptake at pH 7.4 more strongly than
that it did at pH 5.5 (Fig. 9a), and the IC50 value of LVFX at pH
5.5 was about 5-fold higher than that at pH 7.4 (Table 1). The
inhibitory effect of GPFX was also studied. The difference
between the inhibitory effects of GPFX under pH 5.5 and pH 7.4
buffer conditions was more apparent than that of LVFX, and the
inhibitory effect of GPFX at pH 5.5 on L-carnitine uptake was
significantly weaker than that at pH 7.4 (Fig. 9b). Furthermore,
we investigated the kinetic nature of the inhibitory effect of
LVFX on L-carnitine uptake. Eadie–Hofstee plot analysis
showed that LVFX inhibits L-carnitine in a non-competitive
manner (Fig. 10). Nonlinear least-squares analysis showed a Ki
value of 9.0 mM.
3.4. Effect of LVFX on L-carnitine absorption in rats
We investigated whether LVFX has an inhibitory effect on
L-carnitine absorption from the rat intestine. L-Carnitine and
LVFXwere administrated together as described inMaterials andFig. 10. Eadie–Hofstee plot analysis of the effect of LVFX on L-carnitine
uptake. L-[3H]-carnitine (5 nM) uptake at pH 7.4 was measured for 30 min in the
absence (○) or presence (●) of LVFX at 10 mM.Methods. Coadministration of LVFX had no effect on Cmax of L-
carnitine, but Tmax of L-carnitine was delayed significantly from
45 min to 90 min by LVFX coadministration (Fig. 11).
4. Discussion
Although L-carnitine is synthesized by methionine and lysine
in humans, its amount is not sufficient to maintain homeostasis
[28]. Therefore, L-carnitine absorption from dietary sources
in the intestine plays an important role in the maintenance
of L-carnitine homeostasis [3]. It has been reported that L-
carnitine absorption from the intestine is Na+-dependent, sug-
gesting that OCTN2 transports L-carnitine mainly in the intestine
[29,30]. Recently, the expression and characteristics of intestinal
OCTN2 in Caco-2 cells were reported [9]. However, the
mechanism of the substrate recognition and inhibitory mechan-
ism of OCTN2 have not been investigated in detail.
In the first part of this study, we investigated the mRNA
expression levels of OCTN family member and characterized
the L-carnitine transport mechanism in Caco-2 cells. RT-PCR
analysis showed the expression of OCTN2 mRNA. On the other
hand, OCTN1 mRNAwas not detected (Fig. 1). Although it has
been reported that OCTN1 is expressed in Caco-2 cells [31], our
results suggested that the expression level of OCTN1 is much
lower than that of OCTN2 in Caco-2 cells which we used.
OCTN1 is also known to transport L-carnitine in other tissues
[32,33], but the results of our study suggested that OCTN1 had
little contribution to L-carnitine transport. Moreover, while
Elimrani et al. have reported that OCTN2 expression level is
highest in mature Caco-2 cells, the expression of OCTN2
protein was observed clearly by immunocytochemistry (Fig. 2).
Since OCTN2 transports L-carnitine Na+-dependently, we
investigated the uptake of L-carnitine in transport buffer con-
taining Na+ or other cations. While replacement of Cl− with
other anions had no effect on L-carnitine uptake, replacement of
Na+ with other cations significantly decreased L-carnitine uptake
(Fig. 3). Kinetic analysis showed that the half-saturation Na+
concentration, Hill coefficient and Km value were 10.3±
4.5 mM, 1.09 and 8.0±1.0 μM, respectively (Figs. 4 and 5). It
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transport; however, the Km value of ATB
0,+ has been reported to
be 0.83±0.08 mM [10], suggesting that ATB0,+ does not
contribute to L-carnitine transport in our study. Furthermore,
these characteristics and parameter values are similar to those in
studies using HEK293 cells transiently expressing human
OCTN2 [27]. Taking together, these facts suggesting that
OCTN2 contributes greatly to L-carnitine transport in Caco-2
cells.
It has been reported that some zwitterionic drugs inhibit L-
carnitine transport [33]. It has therefore been suggested that
substrate recognition by ionic charge of a drug is one of the
mechanisms by which OCTN2 functions. First, we investigated
the inhibitory effects of structural homologues on L-carnitine
uptake (Fig. 6). Betaine, which is a zwitterionic compound,
strongly inhibited L-carnitine uptake, but glycine and L-lysine
had no inhibitory effect despite the fact that they are zwitterions.
However, trimethyl-L-lysine inhibited L-carnitine uptake.
Furthermore, choline, which is a cationic compound, signifi-
cantly inhibited L-carnitine uptake. L-carnitine, betaine, choline
and trimethyl-L-lysine each have a quaternary amino group in
their cationic structures. but glycine and L-lysine do not. These
facts suggest that the ionic charge of a compound is important
for substrate recognition of OCTN2, but the structure of the
cationic region of a compound is also involved in the substrate
recognition mechanism of OCTN2.
We elucidated the effects of two quinolones (LVFX and
GPFX), which are zwitterions and each have a higher amino
group (tertiary for LVFX and secondary for GPFX) in their
structures, on L-carnitine uptake. LVFX and GPFX have
different pKa values, and the existence ratios of zwitterionic
forms were also found to be different under each pH buffer
condition (Fig. 7). It has been reported that the inhibitory effect
of quinapril (angiotensin-converting enzyme inhibitor) on
PepT1 is changed by its ratio of zwitterionic form [34].
Moreover, Yamaguchi et al. reported that uptake of LVFX and
GPFX in Caco-2 cells under an acidic condition was less than
that under a neutral condition [22]. We therefore hypothesized
that the ratio of zwitterionic form of quinolones is involved in
the inhibitory effect on L-carnitine uptake by OCTN2. Figs. 8
and 9 show the inhibitory effects of LVFX and GPFX on L-
carnitine uptake under pH 5.5 and 7.4 buffer conditions. It was
clear that both quinolones inhibited L-carnitine uptake more
strongly at pH 7.4 than at pH 5.5. Especially GPFX had no
effect on L-carnitine uptake at pH 5.5. The ratios of zwitterionic
forms of LVFX and GPFX were about 65–75% in a neutral
condition but decreases to 39% for LVFX and 2% for GPFX
under an acidic condition (Fig. 7), suggesting that quinolones
need to exist as zwitterions for inhibiting OCTN2 function and
that the inhibitory effect of the cationic form, if any, is weak
(Table 1). It has also been shown that the transport activity of
OCTN2 decreases under an acidic condition [35]. We also
investigated the pH dependence of L-carnitine uptake in Caco-2
cells and found that the amount of L-carnitine uptake at pH 5.5
was decreased to about 60–70% of the control level (data not
shown). However, Km values at pH 7.4 and 5.5 were 8.0±
1.0 μM and 15.5±2.0 μM, respectively, suggesting that pHconditions had little effect on transport activity of OCTN2 in
these inhibitory experiments. We investigated the kinetic nature
of the inhibitory effect of LVFX at pH 7.4. It was clearly shown
that LVFX inhibits L-carnitine transport in a non-competitive
manner (Fig. 10). Some beta-lactam antibiotics have been
suggested to be transported by OCTN2 [36]. However, it has
been reported that GPFX transport in Caco-2 cells is Na+-
independent [22], suggesting that quinolones are not trans-
ported by OCTN2. Ohashi et al. proposed that OCTN2 has both
anion and cation binding sites for zwitterionic compounds [37].
Our results suggest quinolones bind to those site and have an
inhibitory effect on L-carnitine transport. However, because of
their more bulky structures than the structure of L-carnitine,
inhibitory effect of quinolones might not compete to recognition
of L-carnitine by OCTN2. Moreover, an L-carnitine absorption
study using rat intestines showed that LVFX inhibited L-carni-
tine absorption and that Tmax of L-carnitine was delayed
significantly (Fig. 11). Since the acidic condition of the intestine
is maintained in vivo, these results suggest that drugs exist as
zwitterions in a higher ratio under an acidic condition and that a
stronger inhibitory effect on L-carnitine transport might occur.
However, GPFX inhibited L-carnitine uptake more strongly than
did LVFX, while the ratio of zwitterionic forms of both
quinolones are similar under a neutral buffer condition.
Although the results of this study suggested that the ratio of
zwitterionic form and amino group structure are important for
substrate recognition of OCTN2, further investigation is needed
to clarify the difference in affinity of those drugs to OCTN2.
In summary, L-carnitine was found to be mainly transported
by OCTN2 in Caco-2 cells. LVFX and GPFX inhibited L-
carnitine transport via OCTN2 in the ratio of zwitterionic forms
depending manner, suggesting that chemical structures, ionic
charge and structure of cationic region of drugs or compounds
play important roles in the inhibition of L-carnitine transport in
the intestine.References
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